WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, Inc., one of
the world's leading research and advisory firms focusing on pharmaceutical and
health care issues, forecasts that the Crohn's disease drug market will
experience dynamic growth of 73% by 2013. According to the new Pharmacor study
entitled Crohn's Disease, the growth will be a direct result of the launch of
novel biologic agents into the market.
"Several novel biologic agents in late-stage clinical development are
expected to launch for the treatment of Crohn's disease in the next ten
years," said Melissa G. Stolper, analyst at Decision Resources. "The launch of
these emerging agents will expand the number of treatment options for patients
with severe, refractory disease, and physicians will therefore be able to
prescribe second- or third-line biologics for patients who fail to respond to
a first-line biologic. The expanding percentage of patients who will be
treated with biologics and the premium pricing of these new biologics will
help drive composite 2013 sales for these emerging therapies to $843 milllion,
a figure representing almost 50% of the overall Crohn's disease market in that
About Crohn's Disease
Crohn's disease is a chronic, relapsing/remitting inflammatory disease
that predominantly affects the small and large intestines, including the
rectum. In 2003, the diagnosed prevalent population in the seven major
pharmaceutical markets (United States, France, Germany, Italy, Spain, United
Kingdom, and Japan) totaled more than 550,000.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market-
impacting factors and analyzes the commercial outlook for drugs in research
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master their
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources, Inc.
SOURCE Decision Resources, Inc.